Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
Rheumatology (Oxford, England)
|
May 31, 2022
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs
Laura Tucker, Alexander Allen, David Chandler, et al.
Rheumatology (Oxford, England)
|
May 31, 2022
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs
Laura Tucker, Alexander Allen, David Chandler, et al.
Rheumatology (Oxford, England)
|
October 24, 2020
Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
William Tillett, Alexander Allen, Laura Tucker, et al.
Rheumatology (Oxford, England)
|
February 3, 2026
The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established conventional synthetic DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study
Joanne Ablewhite, Georgina Nakafero, Abdullah Almayahi, et al.
Rheumatology Advances in Practice
|
July 15, 2024
The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope
Louise Mercer, Abhishek Abhishek, Akhila Kavirayani, et al.
Rheumatology (Oxford, England)
|
November 14, 2025
The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs
Katie Bechman, Kaiyang Song, Abhishek Abhishek, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
Rheumatology (Oxford, England)
|
May 31, 2022
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs
Laura Tucker, Alexander Allen, David Chandler, et al.
Rheumatology (Oxford, England)
|
May 31, 2022
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs
Laura Tucker, Alexander Allen, David Chandler, et al.
Rheumatology (Oxford, England)
|
October 24, 2020
Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
William Tillett, Alexander Allen, Laura Tucker, et al.
Rheumatology (Oxford, England)
|
February 3, 2026
The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established conventional synthetic DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study
Joanne Ablewhite, Georgina Nakafero, Abdullah Almayahi, et al.
Rheumatology Advances in Practice
|
July 15, 2024
The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope
Louise Mercer, Abhishek Abhishek, Akhila Kavirayani, et al.
Rheumatology (Oxford, England)
|
November 14, 2025
The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs
Katie Bechman, Kaiyang Song, Abhishek Abhishek, et al.
Page
of 3